Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer research"
DOI: 10.1158/0008-5472.can-18-0316
Abstract: MEK inhibition is of interest in cancer drug development, but clinical activity in metastatic colorectal cancer (mCRC) has been limited. Preclinical studies demonstrated Wnt pathway overexpression in KRAS-mutant cell lines resistant to the MEK inhibitor,… read more here.
Keywords: selumetinib; selumetinib cyclosporin; combination selumetinib; cancer ... See more keywords